SAS Output

18-JUN-2018 6:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

STUDY R
E
G
O
P
E
N
ARM TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
ADMIN
S1007-Breast,Adj,N1,Endocrine+/-Chemo 1 Y 1 Recurrence Score testing 9383 204 0 0 0 0 BREAST
        9383 204 0 0 0 0  
 
  2 Y 2 Chemo and Endocrine Therapy 2547 76 0 0 0 0  
      3 Endocrine Therapy Alone 2536 78 0 0 0 0  
        5083 154 0 0 0 0  
 
S1207-Brst,Adj,Endocrine+/-Everolimus 1 Y 1 Blinded drug + Endocrine 808 181 91 46 12 1 BREAST
      2 Blinded drug + Endocrine 817 193 92 49 13 5  
        1625 374 183 95 25 6  
 
S1316-Compar. Effectiv. Trial for MBO 1 Y 1 Randomization Surgery 5 4 1 0 0 0 SURV
      2 Randomization Non-surgical M 5 4 0 0 0 0  
      3 Patient Choice Surgery 45 18 8 3 0 0  
      4 Patient Choice Non-surgical M 100 42 16 2 0 0  
        155 68 25 5 0 0  
 
S1415CD-TrACER CSF Standing Order Intervention for FN 1 Y 1 Site assigned to Cohort 500 279 138 80 20 4 CCD
      2 Site randomized: Control 332 241 91 44 16 3  
      3 SiteRand Int Risk: CSF 590 467 254 125 32 8  
      4 SiteRand Int Risk: No CSF 442 363 178 108 28 8  
        1864 1350 661 357 96 23  
 
S1417CD-Colorectal, Cost Cohort Study 1 Y 1 Observation 261 200 117 64 14 3 CCD
        261 200 117 64 14 3  
 
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 1 Y 1 Tissue for PD-L1 testing 242 207 119 62 17 6 BREAST
        242 207 119 62 17 6  
 
  2 Y 2 Observation 106 90 49 29 10 2  
      3 MK-3475 (Pembrolizumab) 102 86 53 24 11 1  
        208 176 102 53 21 3  
 
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol 1 Y 0 Screening 14 14 11 9 4 1 SURV
        14 14 11 9 4 1  
 
  2 Y 1 Carvedilol 2 2 1 0 0 0  
      2 No intervention 3 3 2 1 0 0  
      3 Observation 9 9 8 8 6 1  
        14 14 11 9 6 1  
 
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 1 Y 1 TICE BCG 36 32 17 9 0 0 GU
      2 Tokyo-172 BCG 37 34 18 12 4 1  
      3 Prime + Tokyo-172 BCG 38 35 19 13 4 1  
        111 101 54 34 8 2  
 
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac 0 Y 0 Pre-Registration 493 133 57 19 4 2 PREV
        493 133 57 19 4 2  
 
  1 Y 1 Blinded drug 61 19 12 5 1 0  
      2 Blinded drug 36 0 0 0 0 0  
      3 Blinded drug 35 0 0 0 0 0  
      4 Blinded drug 65 25 13 6 2 0  
        197 44 25 11 3 0